Design, synthesis and hepatoprotective activity of analogs of the natural product goodyeroside A

Article abstract of DOI:10.3390/molecules18021933

Goodyeroside A, a natural product isolated from the Goodyera species, possesses significant hepatoprotective activity and has a novel skeleton not previously observed in other synthetic drugs used for the treatment of hepatitis. Herein, we report a highly stereoselective synthesis of goodyeroside A and related analogs with varying substituents at the α position of the carbonyl group to explore the structure-activity relationships of goodyeroside A. The absolute configuration of analog 5d was confirmed by single crystal X-ray analysis. The results from in vitro and in vivo studies indicate that 5a, the fully acetylated compound of goodyeroside A, is worthy of further investigation as a lead to identify novel hepatoprotective agents.

Full text of DOI:10.3390/molecules18021933

Molecules 2013, 18, 1933-1948; doi:10.3390/molecules18021933
OPEN ACCESS
molecules
ISSN 1420-3049
www.mdpi.com/journal/molecules
Article
Design, Synthesis and Hepatoprotective Activity of Analogs of
the Natural Product Goodyeroside A
Feng Zhang 1, Bei Han 1, Peng Li 1, Ziyun Lin 1, Dali Yin 1, Yan Li 1, Jialiang Zhong 2 and
Haihong Huang 1,*
1
State Key Laboratory of Bioactive Substance and Function of Natural Medicines & Beijing Key
Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica,
Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China;
E-Mails: zfbj89@gmail.com (F.Z.); terryjordan@163.com (B.H.); qwerlik@imm.ac.cn (P.L.);
linziyun@imm.ac.cn (Z.L.); yindali@imm.ac.cn (D.Y.); yanli@imm.ac.cn (Y.L)
2
Shanghai Institute of Pharmaceutical Industry, Shanghai 200040, China;
E-Mail: jialiang.zhong@yahoo.com.cn
* Author to whom correspondence should be addressed; E-Mail: joyce@imm.ac.cn;
Tel./Fax: +86-010-6316-5244.
Received: 21 December 2012; in revised form: 29 January 2013 / Accepted: 30 January 2013 /
Published: 1 February 2013
Abstract: Goodyeroside A, a natural product isolated from the Goodyera species,
possesses significant hepatoprotective activity and has a novel skeleton not previously
observed in other synthetic drugs used for the treatment of hepatitis. Herein, we report a
highly stereoselective synthesis of goodyeroside A and related analogs with varying
substituents at the α position of the carbonyl group to explore the structure-activity
relationships of goodyeroside A. The absolute configuration of analog 5d was confirmed
by single crystal X-ray analysis. The results from in vitro and in vivo studies indicate that
5a, the fully acetylated compound of goodyeroside A, is worthy of further investigation as
a lead to identify novel hepatoprotective agents.
Keywords: goodyeroside A; structure-activity relationships; stereoselective; single crystal
X-ray

Molecules 2013, 18
1934
1. Introduction
The Goodyera species are orchidaceous perennial herbs grown natively in Japan and Southeast
Asia. Since ancient times, the whole plant has been used as a folk medicine for the treatment of fever,
pain, snake-bites and lung disease [1,2]. In 1999 [3], Gao and coworkers reported the isolation of a
simple aliphatic glucoside, which was characterized as (3S)-3-(β-D-glucopyranosyloxy)butanolide
(goodyeroside A), as a major active compound from the sprouts of Crocus sativus and later from the
plants of three Goodyera species [4]. Preliminary biological tests showed that goodyeroside A had a
significant hepatoprotective effect on primary cultured rat hepatocytes injured by CCl4 [4]. In comparison
to other synthetic drugs used for hepatitis treatment such as bifendatatum [5], bicyclol [6,7] and
lamivudine [8], goodyeroside A has a unique glycoside skeleton (Figure 1). This unique and rather simple
structure evoked our interest in to modifying the structure in order to find new hepatoprotective agents.
Figure 1. Goodyeroside A and some known drugs for hepatitis treatment.
OH
O
O
O
HO
HO
N
NH2
HO
O
HO
N
O
S
O
Lamivudine
goodyeroside A
OCH3
O
OCH3
O
O
O
O
COOCH3
COOCH3
CH2OH
COOCH3
O
O
O
OCH3
Bifendatatum
OCH3
Bicyclol
Recently, the total synthesis of goodyeroside A was reported by Zhang and coworkers [9]. The
development of this synthetic pathway provides opportunities to generate goodyeroside A analogs to
explore their structure-activity relationships as hepatoprotective agents. This paper presents the details
of initial structural modification of goodyeroside A and determination of the absolute configuration
of analogs.
There are several positions in the structure of goodyeroside A that can be modified. We focused on
introducing different substituents at the α position of the carbonyl in the initial stage of the synthesis.
By stereoselectively introducing a series of substituents at the α position of the carbonyl, the
conformation of the molecule can be altered, potentially influencing its hepatoprotective activity. In
order to increase the compound’s lipophilicity, which may be beneficial in improving natural product
pharmacokinetic properties, the fully acetylated products of goodyeroside A and its analogs were
also synthesized.

Molecules 2013, 18
1935
2. Results and Discussion
2.1. The Synthesis of Goodyeroside A and Its Analogs
The synthetic route for goodyeroside A and its derivatives is shown in Scheme 1. The chiral
compound ethyl (S)-4-(tert-butyldimethylsilyloxy)-3-hydroxybutanoate (1) is the key synthon in the
methodology described here and was prepared from (S)-malic acid as described in the literature [9]. The
introduction of an alkyl group at the α position of carbonyl in 1 was improved by reinvestigation of the
reported method [10]. Thus, the β-hydroxy ester was treated with lithium hexamethyldisilazide
(LiHMDS, 2.0 equiv.) in the presence of 1,3-dimethyl-2-imidazolidinone (DMI, 2.5 equiv.) in THF at
−45 °C, and the alkylating agent was then reacted with the dianion generated at the same temperature
to produce the alkylated products 2. Under these reaction conditions, α-alkylation proceeded in a
highly stereoselective manner to give a single diastereoisomer and no stereoisomer was detected.
Scheme 1. The synthetic route for goodyeroside A and its analogs.
OAc
AcO
AcO
O
O
OH OEt
OH OEt
OEt
i
AcO
ii
O
O
O
TBDMSO
R
TBDMSO
TBDMSO
R
1
2b-e
3a-e
OAc
OAc
AcO
AcO
O
AcO
O
OEt
O
R
AcO
O
iv
vi
AcO
AcO
iii
O
O
HO
R
O
5a-e
OH
4a-e
OH
HO
HO
O
O
HO
HO
O
O
R
OEt
v
HO
HO
O
O
O
HO
R
6a-e
7a-e (7a, goodyeroside A)
a: R = H; b: R = CH3-; c: R = CH2=CHCH2-; d: R = C6H5CH2-; e: R = p-MeOC6H4CH2-.
Reagents and Conditions: (i) LiHMDS, DMI, RX, THF, −45 °C; (ii) 2,3,4,6-tetra-O-acetyl-α-D-
glucopyranosyl trichloroacetimidate, 4Å MS, TMSOTf, CH2Cl2, −20 °C~rt; (iii) TBAF/THF, rt;
(iv) PTSA·H2O, 1,4-dioxane, rt; (v) (a): NaOEt/EtOH, rt; (b):TBAF/THF, rt; (vi) PTSA·H2O, 1, 4-dioxane, rt.
Construction of the β-glucoside was accomplished using the imidate method [11]. The use of
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate [12] as glycosyl donor led to the
corresponding β-glucoside 3 in moderate yields. The newly formed glycosidic bonds were proved to
1
be exclusively 1,2-trans on the basis of the H-NMR spectra. Removal of the t-butyldimethylsilyl
(TBDMS) protecting group under acidic conditions such as p-toluenesulfonic acid (PTSA) [13] or
10-camphorsulfonic acid (CSA), generated desired compounds 4 and the lactonized products 5. Even
under neutral conditions such as the use of ceric ammonium nitrate (CAN) [14], a similar mixture of
products 4 and 5 were produced. Only with tetrabutylammonium fluoride (TBAF) [15], were compounds
4 formed cleanly. Treatment of alcohols 4 with PTSA [16] (1.0 equiv.) produced the optically pure

Molecules 2013, 18
1936
cyclization products (2R,3S)-5 and with no detection of epimeric lactones. The absolute configuration
of lactone 5d was determined by X-ray crystallographic analysis.
Initially, we attempted to synthesize compounds 6 from 4 under NaOEt/EtOH conditions, but the
reactions failed to give the desired products. We then inverted the sequence of the silyl and acetyl
deprotections, treated compounds 3 with NaOEt/EtOH to remove the four acetyls, and then treated
with TBAF to achieve desilylation, resulting in pure products 6 from 3 in good yields. The subsequent
cyclization of 6 to obtain 7 was accomplished by PTSA treatment. The spectral data of the acetylated
derivative obtained from 7d under Ac2O/pyridine conditions was identical with that of the
corresponding acetylated compound 5d, which showed that the absolute configuration of deacetylated
lactone 7 was consistent with that of acetylated lactone 5.
2.2. Absolute Configuration of Compound 5d by X-ray Analysis
1
All target compounds were characterized by H-NMR, 13C-NMR and HRMS spectra. A one-
dimensional NOE study performed on compound 5d and 7d showed that the configuration of the
newly generated chiral center C-2 is the R-configuration, deduced from the observation of a positive
NOE at H-3 and H-4a upon irradiation H-2, a positive NOE at H-2, H-4a and H-4b upon irradiation
H-3, and that the extent of positive NOE at H-4a is higher than that of H-4b (Figure 2).
Figure 2. Structures of compounds 5d and 7d.
OAc
H5a
OH
H5a
3''
3''
5''
2''
6''
2''
6''
H5b
H5b
AcO
AcO
O
HO
HO
O
1''
1''
4''
4''
H2
H2
O
O
H3
1' H3
HO
H
1'
H
AcO
5''
H4a
H4b
H4a
H4b
O
O
1
1
O
O
5d
7d
In order to confirm the exact structure of compounds 5, X-ray crystallographic analysis of the
corresponding (2R,3S)-2-benzyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanolide (5d) was
investigated. After various efforts, single crystals of 5d suitable for X-ray analysis were obtained by
slow evaporation of a petroleum ether/EtOAc solution over a period of two weeks. X-ray data were
collected on a Bruker SMART APEX II CCD diffractometer with an Oxford Cryostream low-temperature
device using graphite monochromatic Cu Kα (λ = 1.54178 Ǻ) radiation, operating at 153(2)K, over the
θ range 4.42°–66.00°. The compound 5d crystallized in orthorhombic, space group P212121. Crystal data
of 5d: C25H30O12, molecular weight 522.49, Dc = 1.282g/cm3, a = 1.06142(2) nm, b = 1.10984(2) nm,
c = 2.29714(3) nm, v = 2.70605(8) nm3, z = 4, μ = 0.874, F(000) = 1104. The absolute configuration
was confirmed by the Flack parameter 0.05 (17) and the Hooft parameter 0.04 (6). Full
crystallographic data could be obtained from Acta Crystallographica Section E [17].
The result of the X-ray analysis showed that the bond lengths and angles were in agreement with
literature values [18]. The benzene ring (C6-C11) (ring A) was essentially planar, the five-membered
ring (C1-C4/O2) (ring B) had an envelope conformation, and the six-membered ring (C1'-C5'/O4)
(ring C) was in its chair conformation. The dihedral angels between the various rings were as follows:

Molecules 2013, 18
1937
A/B 112.9(1)°; B/C 110.1(1)°; A/C 13.1(1)°. From the projection of molecular structure, the absolute
configuration was confirmed to be the 2R,3S-configurations (Figure 3).
Figure 3. Perspective view of the crystal structure of compound 5d.
2.3. Biological Results and Discussion
To assess the biological activity of the newly synthesized goodyeroside A analogs as
hepatoprotective agents, a rat hepatic oval cell injury model induced by D-galactosamine (GalN) was
adopted as the induction of liver injuries by GalN is a suitable experimental model of human liver
failure [19]. The reduction in the intracellular level of uridylate is responsible for GalN-induced
apoptosis and necrosis in primary cultured rat hepatocytes [20,21]. Goodyeroside A and its nine
analogs were evaluated for their ability to inhibit GalN-induced hepatocyte injury, using the clinical
hepatoprotective drug Bicyclol as a positive control. Results are shown in Figure 4. At a concentration
of 10−4 M, all the analogs exhibited hepatoprotective activity to certain extents. The fully acetylated
products 5 showed relatively higher activity compared with compounds 7 although the difference was
not significant. Among the fully acetylated products, analogs 5d,e with aromatic substituents at the
α-carbonyl position showed higher activity than analogs 5b,c with small aliphatic substituents at the
α-carbonyl. Goodyeroside A (7a) and its fully acetylated product 5a showed strong hepatoprotective
activity but did not have a significant difference in comparison to bicyclol.
ConA-induced acute liver injury models were used in the present study to investigate the in vivo
activity of goodyeroside A (7a) and its fully acetylated product 5a. As shown in Table 1, compound 5a
exhibited significant hepatoprotective effects as indicated by decreasing ALT and AST levels, while
the natural product goodyeroside A (7a) offered no protection. These results further confirmed our
hypothesis that the full-acetylation may improve pharmacokinetic properties by increasing the
lipophilicity of the compound.

Molecules 2013, 18
Figure 4. Hepatoprotective activity of goodyeroside A and its analogs on GalN-induced rat
1938
hepatocyte injury.
120.00
100.00
80.00
60.00
40.00
20.00
0.00
*
**
**
*
**
###
Compared with Control, ### p < 0.001; Compared with GalN, * p < 0.05, ** p < 0.01.
Table 1. Effects of Bicyclol, 5a and 7a on ConA-induced liver injury in mice
Group
Normal
Untreated
Bicyclol
5a
ALT(U/dL)
21.0 ± 4.1 **
AST(U/dL)
89.8 ± 4.9 **
510.7 ± 120.9
334.7 ± 122.5 *
243.7 ± 30.7 **
nt
612.1 ± 263.4
214.2 ± 123.1 **
164.2 ± 75.1 **
615.4 ± 412.1
7a
* p < 0.05, ** p < 0.01 vs. controls. Bicyclol 200 mg/Kg, 5a 158 mg/Kg, 7a 110 mg/Kg orally. nt: not tested.
3. Experimental
3.1. General
Melting points were determined on a Yanaco micrometer and are uncorrected. NMR spectra were
taken on a Mercury-300, Mercury-400, INOVA-500 or INOVA-600 spectrometers. HRMS spectra
were recorded on an Agilent LC-MSD TOF instrument. The optical rotation was obtained on a
PerkinElmer 341 LC Polarimeter. Flash chromatography was accomplished by using silica gel H and
column chromatography was run on silica gel (200–300 mesh). EtOH was dried by distillation from
Mg. THF was distilled from Na/benzophenone under a N2 atmosphere. CH2Cl2 was dried by distillation
from P2O5.
3.2. General Method for Preparation of Compounds 2
n-Butyllithium (2.5 M, 2.2 equiv.) was added dropwise to a solution of HMDS (2.4 equiv.) in THF
at −10 °C under nitrogen. Then the solution was stirred at rt for 30 min and then cooled to −45 °C. A
solution of the ethyl (S)-4-(tert-butyldimethylsilyloxy)-3-hydroxybutanoate (1, 1.0 equiv.) in THF was

Molecules 2013, 18
1939
added and the residual ester was washed with further THF to the above mixture. After stirring for
30 min at the same temperature, alkylating agent (1.2 equiv.) and 1,3-dimethyl-2-imidazolidinone
(DMI, 2.5 equiv.) in THF were added dropwise. After stirring for 30 min at the same temperature,
saturated aqueous ammonium chloride was added to the reaction mixture and the mixture was
extracted with ethyl acetate. The organic layer was washed with water and saturated brine, dried over
magnesium sulfate, and concentrated in vacuo. The residue was purified by silica gel chromatography
to give the products 2.
Ethyl (2R,3S)-4-(tert-butyldimethylsilyloxy)-3-hydroxy-2-methylbutanoate (2b) [22,23]. Yellow oil,
yield 59%. [α]2D0 −12.49 (c 1.14, CHCl3). H-NMR (300 MHz, CDCl3): δ = 0.10 (s, 6 H, Si(CH3)2),
1
0.94 (s, 9 H, SiC(CH3)3), 1.19 (d, J = 6.9 Hz, 3 H, CHCH3), 1.28 (t, J = 7.2 Hz, 3 H, CH2CH3),
2.60~2.73 (m, 1 H, H-2), 3.60~3.68 (m, 2 H, H-4), 3.71~3.75 (m, 1 H, H-3), 4.18 (q, J = 7.2 Hz, 2 H,
CH2CH3). HRMS (ESI-TOF+): m/z [M+H]+ calcd for C13H29O4Si: 277.1835; found: 277.1807;
[M+Na]+ calcd for C13H28O4SiNa: 299.1655; found: 299.1634.
Ethyl (2R,3S)-2-allyl-4-(tert-butyldimethylsilyloxy)-3-hydroxybutanoate (2c). Pale yellow oil, yield
59%. [α]2D0 −10.28 (c 1.19, CHCl3). H-NMR (300 MHz, CDCl3): δ = 0.06 (s, 6 H, Si(CH3)2), 0.89
1
(s, 9 H, SiC(CH3)3), 1.26 (t, J = 7.2 Hz, 3 H, CH2CH3), 2.31~2.48 (m, 2 H, CH2CH=CH2), 2.63~2.70
(m, 1 H, H-2), 3.60~3.68 (m, 2 H, H-4), 3.74~3.80 (m, 1 H, H-3), 4.08~4.20 (m, 2 H, CH2CH3), 5.07
(dd, J = 10.5, 20.4 Hz, 2 H, CH2CH=CH2), 5.68~5.82 (m, 1 H, CH2CH=CH2). HRMS (ESI-TOF+): m/z
[M+H]+ calcd for C15H31O4Si: 303.1992; found: 303.1963.
Ethyl (2R,3S)-2-benzyl-4-(tert-butyldimethylsilyloxy)-3-hydroxybutanoate (2d). Pale yellow oil, yield
54%. [α]2D0 +17.43 (c 1.00, CHCl3). H-NMR (300 MHz, CDCl3): δ = 0.04 (s, 6 H, Si(CH3)2), 0.89
1
(s, 9 H, SiC(CH3)3), 1.10 (t, J = 7.2 Hz, 3 H, CH2CH3), 2.85~3.00 (m, 2 H, CH2Ph), 3.09 (br s, 1 H,
H-2), 3.65 (d, J = 5.1 Hz, 2 H, H-4), 3.75 (br s, 1 H, H-3), 3.99~4.10 (m, 2 H, CH2CH3), 7.18~7.30
(m, 5 H, Ar-H). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C19H32O4SiNa: 375.1968; found: 375.2007.
Ethyl (2R,3S)-4-(tert-butyldimethylsilyloxy)-3-hydroxy-2-(4-methoxybenzyl)butanoate (2e). Pale yellow
oil, yield 62%. [α]2D0 +16.91 (c 1.45, CHCl3). 1H-NMR (300 MHz, CDCl3): δ = 0.05 (s, 6 H, Si(CH3)2),
0.89 (s, 9 H, SiC(CH3)3), 1.12 (t, J = 7.2 Hz, 3H, CH2CH3), 2.79~2.94 (m, 3 H, H-2, CH2Ph), 3.64 (d,
J = 4.8 Hz, 2 H, H-4), 3.71~3.74 (m, 1 H, H-3), 3.78 (s, 3 H, OCH3), 4.01~4.10 (m, 2 H, CH2CH3),
6.81 (d, J = 6.6 Hz, 2 H, Ar-H), 7.11 (d, J = 6.6 Hz, 2 H, Ar-H). HRMS (ESI-TOF+): m/z [M+H]+
calcd for C20H35O5Si: 383.2254; found: 383.2288.
3.3. General Method for Preparation of Compounds 3
A suspension of 2 (1.0 equiv), 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl trichloroacetimidate
(1.5 equiv.), and activated 4 Å powdered molecular sieves in freshly distilled anhydrous CH2Cl2 was
vigorously stirred for 1 h at rt under nitrogen. To this suspension was added TMSOTf (0.2 equiv.) at
−20 °C. Then the mixture was allowed to warm to rt and stirred at rt for 30 min, the reaction was
quenched with the addition of Et3N. The mixture was filtered and concentrated in vacuo. The residue
was purified by column chromatography to give the products 3.

Molecules 2013, 18
1940
Ethyl (S)-4-(tert-Butyldimethylsilyloxy)-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanoate (3a).
Pale yellow syrup, yield 60%. [α]2D0 −10.1 (c 1.06, CHCl3). H-NMR (300 MHz, CDCl3): δ = 0.04 (s,
1
6 H, Si(CH3)2), 0.89 (s, 9 H, SiC(CH3)3), 1.25 (t, J = 7.2 Hz, 3 H, CH2CH3), 1.99~2.08 (4s, 12 H,
4 × CH3CO), 2.59 (d, J = 6.3 Hz, 2 H, H-2), 3.56 (dd, J = 5.4, 10.5 Hz, 1 H, H-4a), 3.62~3.67 (m, 2 H,
H-4b, H-5'), 4.07 (dd, J = 2.7, 12.3 Hz, 1 H, H-6'a), 4.12 (q, J = 7.2 Hz, 2 H, CH2CH3), 4.10~4.18 (m,
1 H, H-3), 4.27 (dd, J = 4.5, 12.3 Hz, 1 H, H-6'b), 4.75 (d, J = 8.1 Hz, 1 H, H-1'), 4.94 (dd, J = 8.1,
9.3 Hz, 1 H, H-2'), 5.07 (t, J = 9.6 Hz, 1 H, H-4'), 5.16 (t, J = 9.3 Hz, 1 H, H-3'). HRMS (ESI-TOF+):
m/z [M+Na]+ calcd for C26H44O13SiNa: 615.2449; found: 615.2444.
Ethyl (2R,3S)-4-(tert-butyldimethylsilyloxy)-2-methyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)
butanoate (3b). Colorless syrup, yield 65%. [α]2D0 +13.59 (c 1.03, CHCl3). H-NMR (300 MHz,
1
CDCl3): δ = 0.05 (s, 6 H, Si(CH3)2), 0.89 (s, 9 H, SiC(CH3)3), 1.12 (d, J = 6.9 Hz, 3 H, CHCH3), 1.25
(t, J = 7.5 Hz, 3 H, CH2CH3), 1.99~2.07 (4s, 12 H, 4 × CH3CO), 2.78~2.82 (m, 1 H, H-2), 3.62~3.72
(m, 3 H, H-4a, H-4b, H-5'), 4.01~4.15 (m, 4 H, H-3, H-6'a, CH2CH3), 4.18 (dd, J = 5.1, 12.3 Hz, 1 H,
H-6'b), 4.80 (d, J = 7.8 Hz, 1 H, H-1'), 4.95 (dd, J = 7.8, 9.0 Hz, 1 H, H-2'), 5.05 (dd, J = 9.0, 9.6 Hz,
1 H, H-4'), 5.16 (dd, J = 9.0, 9.6 Hz, 1 H, H-3'). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for
C27H46O13SiNa: 629.2605; found: 629.2576.
Ethyl (2R,3S)-2-allyl-4-(tert-butyldimethylsilyloxy)-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)
butanoate (3c). Pale yellow syrup, yield 68%. [α]2D0 −11.55 (c 1.17, CHCl3). H-NMR (300 MHz,
1
CDCl3): δ = 0.06 (s, 6 H, Si(CH3)2), 0.91 (s, 9 H, SiC(CH3)3), 1.24 (t, J = 7.2 Hz, 3 H, CH2CH3),
2.00~2.08 (4s, 12 H, 4 × CH3CO), 2.23~2.46 (m, 2 H, CH2CH=CH2), 2.70~2.76 (m, 1 H, H-2),
3.62~3.66 (m, 1 H, H-5'), 3.68 (dd, J = 5.7, 10.5 Hz, 1 H, H-4a), 3.75 (dd, J = 4.2, 10.5 Hz, 1 H,
H-4b), 3.96~4.01 (m, 1 H, H-3), 4.04~4.17 (m, 3 H, CH2CH3, H-6'a), 4.25 (dd, J = 4.8, 12.3 Hz, 1 H,
H-6'b), 4.80 (d, J = 8.1 Hz, 1 H, H-1'), 4.95 (dd, J = 8.1, 9.6 Hz, 1 H, H-2'), 5.02~5.09 (m, 2 H,
CH2CH=CH2), 5.06 (dd, J = 9.3, 9.6 Hz, 1 H, H-4'), 5.16 (dd, J = 9.3, 9.6 Hz, 1 H, H-3'), 5.67~5.81
(m, 1 H, CH2CH=CH2). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C29H48O13SiNa: 655.2762; found:
655.2755.
Ethyl (2R,3S)-2-benzyl-4-(tert-butyldimethylsilyloxy)-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)
butanoate (3d). Pale yellow syrup, yield 76%. [α]2D0 −11.9 (c 1.03, CHCl3). H-NMR (300 MHz,
1
CDCl3): δ = 0.04 (s, 6 H, Si(CH3)2), 0.88 (s, 9 H, SiC(CH3)3), 1.14 (t, J = 7.2 Hz, 3 H, CH2CH3),
2.00~2.08 (4s, 12 H, 4 × CH3CO), 2.93 (m, 2 H, H-2, CH2Ph), 3.00 (dd, J = 4.2, 7.5 Hz, 1 H, CH2Ph),
3.64~3.68 (m, 1 H, H-5'), 3.72 (d, J = 11.1 Hz, 1 H, H-4a), 3.77 (dd, J = 4.5, 11.1 Hz, 1 H, H-4b),
3.96~4.08 (m, 3 H, H-3, CH2CH3), 4.13 (dd, J = 2.1, 12.3 Hz, 1 H, H-6'a), 4.28 (dd, J = 4.5, 12.3 Hz,
1 H, H-6'b), 4.82 (d, J = 7.8 Hz, 1 H, H-1'), 5.00 (dd, J = 7.8, 9.0 Hz, 1 H, H-2'), 5.10 (dd, J = 9.3 Hz,
1 H, H-4'), 5.18 (dd, J = 9.0, 9.3 Hz, 1 H, H-3'), 7.14~7.24 (m, 5 H, Ar-H). HRMS (ESI-TOF+): m/z
[M+Na]+ calcd for C33H50O13SiNa: 705.2918; found: 705.2938.
Ethyl (2R,3S)-4-(tert-butyldimethylsilyloxy)-2-(4-methoxybenzyl)-3-(2,3,4,6-tetra-O-acetyl-β-D-gluco-
pyranosyloxy)butanoate (3e). Pale yellow syrup, yield 67%. [α] 2D0 −10.70 (c 1.39, CHCl3).
1H-NMR (300 MHz, CDCl3): δ = 0.04 (s, 6 H, Si(CH3)2), 0.89 (s, 9 H, SiC(CH3)3), 1.16 (t, J = 7.2 Hz,
3 H, CH2CH3), 2.00~2.06 (4s, 12 H, 4 × CH3CO), 2.85~2.88 (m, 2 H, H-2, CH2Ph), 2.95 (dd, J = 3.9,

Molecules 2013, 18
1941
7.2 Hz, 1 H, CH2Ph), 3.64~3.68 (m, 1 H, H-5'), 3.77 (s, 3 H, OCH3), 3.79~3.80 (m, 2 H, H-4a, H-4b),
3.95~4.00 (m, 1 H, H-3), 4.04 (q, J = 7.2 Hz, 2 H, CH2CH3), 4.09~4.16 (m, 1 H, H-6'a), 4.28 (dd,
J = 4.5, 12.0 Hz, 1 H, H-6'b), 4.83 (d, J = 7.8 Hz, 1 H, H-1'), 5.00 (dd, J = 7.8, 8.7 Hz, 1 H, H-2'), 5.10
(t, J = 9.3 Hz, 1 H, H-4'), 5.18 (dd, J = 9.0, 9.3 Hz, 1 H, H-3'), 6.78 (d, J = 8.4 Hz, 2 H, Ar-H), 7.11
(d, J = 8.4 Hz, 2 H, Ar-H). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C34H52O14SiNa: 735.3024;
found: 735.3067.
3.4. General Method for Preparation of Compounds 4
To a solution of 3 (1.0 equiv) in anhydrous THF was added TBAF (1.0 M in THF, 0.5 equiv). The
mixture was stirred at rt until TLC showed no starting material. Then the mixture was concentrated in
vacuo. The residue was purified by column chromatography to give the products 4.
Ethyl (S)-4-hydroxy-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanoate (4a). Yellow syrup,
yield 60%. [α]2D0 −10.87 (c 1.01, CHCl3). H-NMR (300 MHz, CDCl3): δ = 1.27 (t, J = 7.2 Hz, 3 H,
1
CH2CH3), 2.01~2.09 (4s, 12 H, 4 × CH3CO), 2.54 (dd, J = 6.6, 16.5 Hz, 1 H, H-2a), 2.74 (dd, J = 3.0,
16.5 Hz, 1 H, H-2b), 3.58 (dd, J = 6.6, 12.0 Hz, 1 H, H-4a), 3.66 (dd, J = 3.0, 12.0 Hz, 1 H, H-4b),
3.68~3.72 (m, 1 H, H-5'), 4.06~4.22 (m, 4 H, H-6'a, CH2CH3, H-3), 4.26 (dd, J = 4.5, 12.3 Hz, 1 H,
H-6'b), 4.74 (d, J = 8.1 Hz, 1 H, H-1'), 4.97 (dd, J = 8.1, 9.3 Hz, 1 H, H-2'), 5.07 (dd, J = 9.6, 9.9 Hz, 1
H, H-4'), 5.21 (dd, J = 9.3, 9.6 Hz, 1 H, H-3'). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for
C20H30O13Na: 501.1584; found: 501.1599.
Ethyl (2R,3S)-4-hydroxy-2-methyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanoate (4b).
Yellow syrup, yield 50%. [α]2D0 −14.39 (c 3.21, CHCl3). H-NMR (300 MHz, CDCl3): δ = 1.14 (d,
1
J = 9.0 Hz, 3 H, CHCH3), 1.26 (t, J = 7.2 Hz, 3 H, CH2CH3), 2.00~2.09 (4s, 12 H, 4 × CH3CO), 2.89
(m, 1 H, H-2), 3.67~3.80 (m, 3 H, H-4a, H-4b, H-5'), 4.01~4.41 (m, 4 H, H-3, H-6'a, CH2CH3), 4.63
(dd, J = 8.4, 16.8 Hz, 1 H, H-6'b), 4.74 (d, J = 8.4 Hz, 1 H, H-1'), 5.02 (dd, J = 8.4, 9.0 Hz, 1 H, H-2'),
5.09 (dd, J = 9.9, 10.8 Hz, 1 H, H-4'), 5.17 (dd, J = 9.0, 9.9 Hz, 1 H, H-3'). HRMS (ESI-TOF+): m/z
[2M+Na]+ calcd for C42H64O26Na: 1007.3584; found: 1007.3549.
Ethyl (2R,3S)-2-allyl-4-hydroxy-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanoate (4c). Pale
yellow syrup, yield 75%. [α]2D0 −20.45 (c 2.92, CHCl3). H-NMR (300 MHz, CDCl3): δ = 1.24 (t,
1
J = 7.5 Hz, 3 H, CH2CH3), 1.98~2.06 (4s, 12 H, 4 × CH3CO), 2.33 (dd, J = 6.9, 7.2 Hz, 2 H,
CH2CH=CH2), 2.82 (m, 1 H, H-2), 3.61~3.72 (m, 3 H, H-4a, H-4b, H-5'), 3.98 (q, J = 4.2, 5.7 Hz, 1 H,
H-3), 4.08~4.20 (m, 3 H, CH2CH3, H-6'a), 4.21 (dd, J = 5.4, 12.3 Hz, 1 H, H-6'b), 4.69 (d, J = 7.8 Hz,
1 H, H-1'), 4.93~5.08 (m, 4 H, H-2', H-4', CH2CH=CH2), 5.18 (dd, J = 9.3, 9.6 Hz, 1 H, H-3'),
5.64~5.78 (m, 1 H, CH2CH=CH2). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C23H34O13Na:
541.1897; found: 541.1866.
Ethyl (2R,3S)-2-benzyl-4-hydroxy-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanoate (4d).
Colorless syrup, yield 74%. [α]2D0 −5.81 (c 1.15, CHCl3). H-NMR (300 MHz, CDCl3): δ = 1.11 (t,
1
J = 7.2 Hz, 3 H, CH2CH3), 2.01~2.19 (4s, 12 H, 4 × CH3CO), 2.87 (dd, J = 10.5, 13.5 Hz, 1 H,
CH2Ph), 2.96 (dd, J = 4.8, 13.5 Hz, 1 H, CH2Ph), 3.10~3.16 (m, 1 H, H-2), 3.73~3.77 (m, 3 H, H-4a,

Molecules 2013, 18
1942
H-4b, H-5'), 3.96~4.06 (m, 3 H, H-3, CH2CH3), 4.13 (dd, J = 2.4, 12.3 Hz, 1 H, H-6'a), 4.26 (dd,
J = 5.1, 12.3 Hz, 1 H, H-6'b), 4.75 (d, J = 7.8 Hz, 1 H, H-1'), 5.04 (dd, J = 7.8, 9.6 Hz, 1 H, H-2'), 5.10
(dd, J = 9.6, 9.9 Hz, 1 H, H-4'), 5.23 (dd, J = 9.3, 9.6 Hz, 1 H, H-3'), 7.17~7.24 (m, 5 H, Ar-H). HRMS
(ESI-TOF+): m/z [M+Na]+ calcd for C27H36O13Na: 591.2054; found: 591.2021.
Ethyl (2R,3S)-4-hydroxy-2-(4-methoxybenzyl)-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanoate
(4e). Colorless syrup, yield 67%. [α]D20 −0.77 (c 1.29, CHCl3). 1H-NMR (300 MHz, CDCl3): δ = 1.12 (t,
J = 7.2 Hz, 3 H, CH2CH3), 2.00~2.12 (4s, 12 H, 4 × CH3CO), 2.80 (dd, J = 10.2, 13.5 Hz, 1 H,
CH2Ph), 2.89 (dd, J = 4.5, 13.5 Hz, 1 H, CH2Ph), 3.03~3.10 (m, 1 H, H-2), 3.72~3.73 (m, 3 H, H-4a,
H-4b, H-5'), 3.76 (s, 3 H, OCH3), 3.99~4.06 (m, 3 H, CH2CH3, H-3), 4.13 (dd, J = 1.8, 12.3 Hz, 1 H,
H-6'a), 4.25 (dd, J = 5.1, 12.3 Hz, 1 H, H-6'b), 4.74 (d, J = 7.8 Hz, 1 H, H-1'), 5.02 (dd, J = 7.8, 9.6
Hz, 1 H, H-2'), 5.09 (m, 1 H, H-4'), 5.21 (m, 1 H, H-3'), 6.77 (d, J = 8.7 Hz, 2 H, Ar-H), 7.09 (d,
J = 8.7 Hz, 2 H, Ar-H). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C28H38O14Na: 621.2159; found:
621.2183.
3.5. General Method for Preparation of Compounds 5
To a solution of 4 (1.0 equiv.) in 1,4-dioxane was added PTSA·H2O (1.0 equiv.). The mixture was
stirred at rt until TLC showed no starting material. Then the mixture was concentrated in vacuo. The
residue was purified by column chromatography to give the products 5.
(3S)-3-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyloxy)butanolide (5a). White solid, yield 58%. Mp
126.5–127.5 °C (lit. [24] 126–127.5 °C); [α]2D0 −43.7 (c 1.01, CHCl3) (lit. [24] [α]1D5 −47.4 (c 0.09,
1
CHCl3)). H-NMR (300 MHz, CDCl3): δ = 2.01~2.10 (4s, 12 H, 4 × CH3CO), 2.74~2.75 (m, 2 H,
H-2), 3.69~3.74 (m, 1 H, H-5'), 4.15 (dd, J = 2.1, 12.3 Hz, 1 H, H-6'a), 4.24 (dd, J = 2.1, 12.3 Hz, 1 H,
H-6'b), 4.31 (dd, J = 2.1, 10.5 Hz, 1 H, H-4a), 4.39 (dd, J = 1.8, 10.5 Hz, 1 H, H-4b), 4.63 (m, 2 H,
H-1', H-3), 4.99 (dd, J = 7.8, 9.6 Hz, 1 H, H-2'), 5.08 (dd, J = 9.6, 9.9 Hz, 1 H, H-4'), 5.21 (dd, J = 9.3,
9.9 Hz, 1 H, H-3'). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C18H24O12Na: 455.1165; found:
455.1131.
(2R,3S)-2-Methyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanolide (5b). White solid, yield
61%. Mp 150–151 °C; [α]2D0 −69.45 (c 0.53, CHCl3). H-NMR (300 MHz, CDCl3): δ = 1.24 (d,
1
J = 7.0 Hz, 3 H, CHCH3), 2.01~2.09 (m, 12 H, 4 × CH3CO), 2.63~2.73 (m, 1 H, H-2), 3.66~3.72 (m, 1
H, H-5'), 4.14~4.24 (m, 3 H, H-6'a, H-6'b, H-4a), 4.30 (d, J = 5.1 Hz, 1 H, H-4b), 4.57 (dd, J = 3.0, 5.1
Hz, 1 H, H-3), 4.63(d, J = 8.1 Hz, 1 H, H-1'), 4.99 (dd, J = 8.1, 9.3 Hz, 1 H, H-2'), 5.10 (dd, J = 9.3,
9.6 Hz, 1 H, H-4'), 5.21 (dd, J = 9.3, 9.3 Hz, 1 H, H-3'). 13C-NMR (125 MHz, CDCl3): δ = 13.2, 18.4,
20.5, 20.7, 41.2, 58.4, 61.9, 68.2, 69.9, 70.8, 72.2, 72.5, 80.8, 99.9, 169.1, 169.3, 170.2, 170.5, 177.3.
HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C19H26O12Na: 469.1322; found: 469.1287.
(2R,3S)-2-Allyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanolide (5c). White solid, yield
38%. Mp 143–144 °C; [α]2D0 −80.3 (c 0.76, CHCl3). H-NMR (300 MHz, CDCl3): δ = 2.00~2.08 (m,
1
12 H, 4 × CH3CO), 2.42~2.50 (m, 2 H, CH2CH=CH2), 2.56~2.61 (m, 1 H, H-2), 3.67~3.70 (d,
J = 9.3 Hz, 1 H, H-5'), 4.18 (m, 3 H, H-6'a, H-6'b, H-4a), 4.30 (d, J = 10.8 Hz, 1 H, H-4b), 4.61 (m, 2

Molecules 2013, 18
1943
H, H-3, H-1'), 4.98 (dd, J = 8.1, 9.0 Hz, 1 H, H-2'), 5.07 (dd, J = 9.3, 9.6 Hz, 1 H, H-4'), 5.14~5.24 (m,
13
3 H, H-3', CH2CH=CH2), 5.79~5.93 (m, 1 H, CH2CH=CH2). C-NMR(125 MHz, CDCl3): δ = 18.4,
20.5, 20.6, 20.7, 27.7, 44.3, 61.7, 68.3, 70.4, 70.9, 72.0, 72.4, 74.1, 98.1, 117.4, 134.5, 169.1, 169.3,
170.3, 170.5, 176.0. HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C21H28O12Na: 495.1478; found:
495.1437.
(2R,3S)-2-Benzyl-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanolide (5d). White solid, yield
64%. Mp 202–203 °C; [α]2D0 −108.0 (c 1.07, CHCl3). H-NMR (300 MHz, CDCl3): δ = 2.03~2.09 (4s,
1
12 H, 4×CH3CO), 2.71~2.78 (m, 1 H, H-2), 3.01 (dd, J = 10.5, 13.8 Hz, 1 H, CH2Ph), 3.10 (dd,
J = 3.6, 13.8 Hz, 1 H, CH2Ph), 3.63~3.71 (m, 1 H, H-5'), 4.10~4.16 (m, 2 H, H-4a, H-6'a), 4.24 (dd,
J = 4.5, 12.3 Hz, 1 H, H-6'b), 4.32 (d, J = 10.8 Hz, 1 H, H-4b), 4.46~4.51 (m, 1 H, H-3), 4.62 (d,
J = 8.1 Hz, 1 H, H-1'), 5.08 (dd, J = 8.1, 9.0 Hz, 1 H, H-2'), 5.16 (m, 1 H, H-4'), 5.24 (m, 1 H, H-3'),
13
7.20~7.34 (m, 5 H, Ar-H). C-NMR (125 MHz, CDCl3): δ = 20.4, 20.5, 20.6, 20.7, 29.1, 47.1, 61.9,
68.2, 70.1, 71.0, 72.1, 72.4, 73.9, 98.0, 126.6, 128.4, 128.4, 129.1, 129.1, 138.9, 169.2, 169.3, 170.3,
170.6, 175.7. HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C25H30O12Na: 545.1635; found: 545.1639.
(2R,3S)-2-(4-Methoxybenzyl)-3-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyloxy)butanolide (5e). White
solid, yield 58%. Mp 169–170°C; [α]D20 −116.4 (c 0.87, CHCl3). H-NMR (300 MHz, CDCl3):
1
δ = 2.02~2.09 (4s, 12 H, 4 × CH3CO), 2.67~2.72 (m, 1 H, H-2), 2.95 (dd, J = 10.2, 14.1 Hz, 1 H,
CH2Ph), 3.52 (dd, J = 4.2, 14.1 Hz, 1 H, CH2Ph), 3.70 (m, 1 H, H-5'), 3.77 (s, 3 H, OCH3), 4.10~4.16
(m, 2 H, H-4a, H-6'a), 4.24 (dd, J = 4.2, 12.3 Hz, 1 H, H-6'b), 4.29 (d, J = 11.1 Hz, 1 H, H-4b), 4.48
(m, 1 H, H-3), 4.62 (d, J = 8.1 Hz, 1 H, H-1'), 5.08 (dd, J = 8.1, 9.0 Hz, 1 H, H-2'), 5.15 (t, J = 9.3 Hz,
1 H, H-4'), 5.24 (dd, J = 9.0, 9.3 Hz, 1 H, H-3'), 6.79 (d, J = 8.1 Hz, 2 H, Ar-H), 7.24 (d, J = 8.1 Hz, 2
13
H, Ar-H). C-NMR (125 MHz, CDCl3): δ = 20.5. 20.5, 20.6, 20.7, 32.5, 48.0, 55.2, 61.9, 68.0, 70.9,
71.0, 72.2, 72.4, 76.8, 100.0, 114.2, 114.2, 128.7, 130.3, 130.3, 158.8, 169.0, 169.3, 170.2, 170.5,
176.7. HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C26H32O13Na: 575.1741; found: 575.1750.
3.6. General Method for Preparation of Compounds 6
To a solution of 3 (1.0 equiv) in absolute EtOH was added NaOEt (1.0 M in EtOH, 0.2 equiv). The
mixture was stirred at rt until TLC showed no starting material. Then the solution was neutralized with
DOWEX® 50WX-4. The resin was filtered off and the solvent was removed in vacuo. The residue and
TBAF (1.0 M in THF, 0.5 equiv) were dissolved in THF and stirred at rt until TLC showed no starting
material. After removal of the solvent in vacuo, the residue was purified by column chromatography to
give the products 6.
Ethyl (S)-3-(β-D-glucopyranosyloxy)-4-hydroxybutanoate (6a). Pale yellow solid, yield 52%. Mp
96–97 °C; [α]2D0 −26.32 (c 0.46, CH3OH). 1H-NMR (300 MHz, CD3OD): δ = 1.17 (t, J = 7.2 Hz, 3 H,
CH2CH3), 2.50 (dd, J = 6.0, 15.9 Hz, 1 H, H-2a), 2.63 (dd, J = 7.2, 15.9 Hz, 1 H, H-2b), 3.09 (dd,
J = 7.6, 9.0 Hz, 1 H, H-2'), 3.16~3.27 (m, 3 H, H-5', H-4', H-3'), 3.48~3.60 (m, 3 H, H-4a, H-6'a,
H-6'b), 3.74(d, J = 10.8 Hz, 1 H, H-4b), 4.05 (q, J = 7.2 Hz, 2 H, CH2CH3), 4.11 (m, 1 H, H-3), 4.34
(d, J = 7.5 Hz, 1 H, H-1'). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C12H22O9Na: 333.1162;
found: 333.1132.

Molecules 2013, 18
1944
Ethyl (2R,3S)-3-(β-D-glucopyranosyloxy)-4-hydroxy-2-methylbutanoate (6b). White solid, yield 77%.
Mp 104–106°C; [α]2D0 −38.0 (c 0.96, CH3OH). 1H-NMR (300 MHz, pyridine-d5): δ = 1.11 (t, J = 7.5 Hz,
3 H, CH2CH3), 1.29 (d, J = 6.9 Hz, 3 H, CHCH3), 3.15~3.24 (m, 1 H, H-2), 3.90 (br s, 1 H, H-5'),
4.01~4.06 (m, 2 H, H-2', H-4a), 4.10~4.22 (m, 5 H, H-4b, CH2CH3, H-4', H-3'), 4.32 (dd, J = 6.0,
12.0 Hz, 1 H, H-6'a), 4.48~4.51 (m, 2 H, H-6'b, H-3), 5.14 (d, J = 7.8 Hz, 1 H, H-1'), 5.70 (br s, 5 H,
5×OH). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C13H24O9Na: 347.1318; found: 347.1305.
Ethyl (2R,3S)-2-allyl-3-(β-D-glucopyranosyloxy)-4-hydroxybutanoate (6c). Pale yellow syrup, yield
69%. [α]2D0 −19.96 (c 0.89, EtOH). H-NMR (300 MHz, CD3OD): δ = 1.19 (t, J = 7.2 Hz, 3 H,
1
CH2CH3), 2.24~2.33 (m, 2 H, CH2CH=CH2), 2.77~2.85 (m, 1 H, H-2), 3.01~3.32 (m, 4 H, H-2', H-5',
H-4', H-3'), 3.51~3.61 (m, 2 H, H-4a, H-6'a), 3.70~3.80 (m, 2 H, H-4b, H-6'b), 3.87~3.92 (m, 1 H,
H-3), 4.02~4.13 (m, 2 H, CH2CH3), 4.33 (d, J = 7.8 Hz, 1 H, H-1'), 4.98 (dd, J = 10.2, 17.1 Hz, 2 H,
CH2CH=CH2), 5.63~5.77 (m, 1 H, CH2CH=CH2). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for
C15H26O9Na: 373.1475; found: 373.1439.
Ethyl (2R,3S)-2-benzyl-3-(β-D-glucopyranosyloxy)-4-hydroxybutanoate (6d). White solid, yield 77%.
Mp 140–141°C; [α]2D0 +11.13 (c 0.82, CH3OH). 1H-NMR (300 MHz, pyridine-d5): δ = 0.96 (t, J = 7.2 Hz,
3 H, CH2CH3), 3.20 (dd, J = 10.5, 13.5 Hz, 1 H, CH2Ph), 3.31 (dd, J = 4.8, 13.5 Hz, 1 H, CH2Ph),
3.47~3.54 (m, 1 H, H-2), 3.84~3.89 (m, 1 H, H-5'), 3.95~4.13 (m, 3 H, H-4a, CH2CH3), 4.16~4.26 (m,
4 H, H-2', H-4b, H-4', H-3'), 4.34 (dd, J = 5.4, 11.7 Hz, 1 H, H-6'a), 4.49~4.57 (m, 2 H, H-6'b, H-3),
5.15 (d, J = 7.8 Hz, 1 H, H-1'), 6.31 (br s, 5 H, 5 × OH), 7.19~7.45 (m, 5 H, Ar-H). HRMS (ESI-
TOF+): m/z [M+Na]+ calcd for C19H28O9Na: 423.1631; found: 423.1607.
Ethyl (2R,3S)-3-(β-D-glucopyranosyloxy)-4-hydroxy-2-(4-methoxybenzyl)butanoate (6e). White solid,
yield 75%. Mp 150–151°C; [α]2D0 +8.0 (c 0.21, CH3OH). H-NMR (300 MHz, CD3OD): δ = 0.98 (t,
1
J = 7.2 Hz, 3 H, CH2CH3), 2.65 (dd, J = 11.4, 13.2 Hz, 1 H, CH2Ph), 2.81 (dd, J = 4.8, 13.2 Hz, 1 H,
CH2Ph), 2.95~3.06 (m, 1 H, H-2), 3.10~3.30 (m, 4 H, H-5', H-2', H-4', H-3'), 3.55 (dd, J = 5.1, 11.4
Hz, 1 H, H-4a), 3.61~3.66 (m, 1 H, H-6'a), 3.66 (s, 3 H, OCH3), 3.73~3.79 (m, 2 H, H-6'b, H-4b),
3.87~3.94 (m, 3 H, CH2CH3, H-3), 4.32 (d, J = 8.1 Hz, 1 H, H-1'), 6.72 (d, J = 8.4 Hz, 2 H, Ar-H),
7.03 (d, J = 8.1 Hz, 2 H, Ar-H). HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C20H30O10Na: 453.1737;
found: 453.1745.
3.7. General Method for Preparation of Compounds 7
To a solution of 6 (1.0 equiv.) in 1,4-dioxane was added PTSA·H2O (1.0 equiv.). The mixture was
stirred at rt until TLC showed no starting material. Then the mixture was concentrated in vacuo. The
residue was purified by column chromatography to give the products 7.
(3S)-3-(β-D-Glucopyranosyloxy)butanolide (goodyeroside A, 7a). White solid, yield 63%. Mp 154–155 °C
(lit. [4] 156–157°C); [α]2D0 −72.7 (c 0.59, H2O) (lit. [4] [α]D20 −71.2 (c 0.55, H2O)). 1H-NMR (500 MHz,
pyridine-d5): δ = 2.86 (dd, J = 5.5, 18.0 Hz, 1 H, H-2a), 2.91 (d, J = 18.0 Hz, 1 H, H-2b), 3.93 (br s,
1 H, H-5'), 3.97 (m, 1 H, H-2'), 4.18~4.23 (m, 2 H, H-3', H-4'), 4.34 (m, 1 H, H-6'a), 4.35 (dd, J = 4.5,
10.0 Hz, 1 H, H-4a), 4.54 (dd, J = 1.5, 11.5 Hz, 1 H, H-6'b), 4.63 (d, J = 10.0 Hz, 1 H, H-4b), 4.86

Molecules 2013, 18
1945
(m, 1 H, H-3), 4.92 (d, J = 7.5 Hz, 1 H, H-1'). 13C-NMR (125 MHz, pyridine-d5): δ = 36.4, 62.7, 71.4,
74.0, 74.6, 74.7, 78.3, 78.7, 103.6, 176.3. HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C10H16O8Na:
287.0743; found: 287.0750.
(2R,3S)-3-(β-D-Glucopyranosyloxy)-2-methylbutanolide (7b). White solid, yield 77%. Mp 126–127 °C;
[α]2D0 −68.69 (c 0.98, CH3OH). H-NMR (300 MHz, pyridine-d5): δ = 1.30 (d, J = 6.9 Hz, 3 H,
1
CHCH3), 2.78~2.90 (m, 1 H, H-2), 3.94~3.99 (m, 2 H, H-5', H-2'), 4.15~4.27 (m, 3 H, H-3', H-4', H-4a),
4.36 (dd, J = 8.7, 12.0 Hz, 1 H, H-6'a), 4.58 (d, J = 12.0 Hz, 1 H, H-6'b), 4.72 (d, J = 10.5 Hz, 1 H, H-4b),
13
4.84 (m, 1 H, H-3), 4.91 (d, J = 7.5 Hz, 1 H, H-1'), 6.13 (br s, 4 H, 4 × OH). C-NMR (100 MHz,
pyridine-d5): δ = 9.1, 39.3, 62.8, 71.4, 72.1, 74.5, 76.0, 78.4, 78.8, 102.7, 178.9. HRMS (ESI-TOF+):
m/z [M+Na]+ calcd for C11H18O8Na: 301.0899; found: 301.0866.
(2R,3S)-2-Allyl-3-(β-D-glucopyranosyloxy)butanolide (7c). Colorless oil, yield 58%. [α]2D0 −67.84 (c
1
3.36, CH3OH). H-NMR (300 MHz, CD3OD): δ = 2.25~2.40 (m, 2 H, CH2CH=CH2), 2.68 (m, 1 H,
H-2), 3.06~3.22 (m, 4 H, H-5', H-2', H-4', H-3'), 3.51~3.58 (m, 1 H, H-6'a), 3.80 (d, J = 11.1 Hz, 1 H,
H-6'b), 4.18~4.22 (m, 1 H, H-4a), 4.29 (d, J = 7.2 Hz, 1 H, H-1'), 4.39 (d, J = 10.2 Hz, 1 H, H-4b),
4.68 (m, 1 H, H-3), 5.02 (dd, J = 10.8, 16.8 Hz, 2 H, CH2CH=CH2), 5.94 (m, 1 H, CH2CH=CH2).
13C-NMR(125 MHz, pyridine-d5): δ = 28.5, 44.6, 62.9, 71.6, 72.4, 74.6, 75.2, 78.4, 78.7, 102.8, 116.7,
136.5, 177.6. HRMS (ESI-TOF+): m/z [M+Na]+ calcd for C13H20O8Na: 327.1050; found: 327.1057.
(2R,3S)-2-Benzyl-3-(β-D-glucopyranosyloxy)butanolide (7d). White solid, yield 85%. Mp 150–151 °C;
[α]2D0 −120.44 (c 0.36, CH3OH). H-NMR (600 MHz, pyridine-d5): δ = 3.02~3.06 (m, 1 H, H-2), 3.26
1
(dd, J = 3.6, 13.8 Hz, 1 H, CH2Ph), 3.34 (dd, J = 10.2, 13.8 Hz, 1 H, CH2Ph), 3.91~3.93 (m, 1 H, H-5'),
4.02 (dd, J = 7.8, 8.4 Hz, 1 H, H-2'), 4.20~4.25 (m, 3 H, H-4', H-3', H-4a), 4.38 (dd, J = 5.4, 12.0 Hz, 1
H, H-6'a), 4.56 (dd, J = 2.4, 12.0 Hz, 1 H, H-6'b), 4.73~4.74 (m, 1 H, H-3), 4.82 (d, J = 10.2 Hz, 1 H,
H-4b), 4.90 (d, J = 7.2 Hz, 1 H, H-1'), 6.32 (br s, 4 H, 4 × OH), 7.24 (m, 1 H, Ar-H), 7.41 (m, 2 H, Ar-
H), 7.64 (m, 2 H, Ar-H). 13C-NMR (125 MHz, pyridine-d5): δ = 30.0, 47.4, 63.1, 64.5, 71.6, 72.3, 74.6,
75.1, 78.4, 78.6, 103.0, 126.7, 128.8, 128.8, 129.9, 140.4, 177.4. HRMS (ESI-TOF+): m/z [M+Na]+
calcd for C17H22O8Na: 377.1212; found: 377.1214.
(2R,3S)-3-(β-D-Glucopyranosyloxy)-2-(4-methoxybenzyl)butanolide (7e). White solid, yield 94%. Mp
186–187 °C; [α]2D0 −110.64 (c 0.38, CH3OH). 1H-NMR (300 MHz, pyridine-d5): δ = 3.00~3.07 (m, 1 H,
H-2), 3.23 (dd, J = 3.9, 14.1 Hz, 1 H, CH2Ph), 3.32 (dd, J = 9.6, 14.1 Hz, 1 H, CH2Ph), 3.64 (s, 3 H,
OCH3), 3.94 (m, 1 H, H-5'), 3.98~4.03 (m, 1 H, H-2'), 4.19~4.24 (m, 3 H, H-4', H-3', H-4a), 4.39 (dd,
J = 5.1, 11.4 Hz, 1 H, H-6'a), 4.57 (d, J = 11.4 Hz, 1 H, H-6'b), 4.77~4.80 (m, 1 H, H-3), 4.83 (d,
J = 10.2 Hz, 1 H, H-4b), 4.92 (d, J = 7.5 Hz, 1 H, H-1'), 7.07 (d, J = 8.1 Hz, 2 H, Ar-H), 7.61 (d,
J = 8.7 Hz, 2 H, Ar-H). 13C-NMR (125 MHz, pyridine-d5): δ = 29.2, 47.6, 55.1, 63.1, 64.5, 71.7, 72.3,
74.7, 75.2, 78.4, 78.6, 103.0, 109.7, 114.4, 131.0, 132.4, 158.8, 177.4. HRMS (ESI-TOF+): m/z
[M+Na]+ calcd for C18H24O9Na: 407.1318; found: 407.1357.

Molecules 2013, 18
1946
3.8. General Method for Preparation of Compound 5d from Compound 7d
A solution of 7d in Ac2O and dry pyridine was stirred at rt overnight. Then the reaction was
quenched with the aqueous CuSO4 and extracted with ethyl acetate. The combined organic layer was
washed with 0.05 M HCl and saturated aqueous NaCl, dried over Na2SO4. The solution was filtered
and concentrated in vacuo. The residue was purified by column chromatography to give the product 5d
as a white solid in 95% yield.
3.9. Bioassay Methods
3.9.1. Hepatoprotective Activities against D-Galactosamine-Induced Cytotoxicity in WB-F344 Cells
The hepatoprotective activities were determined using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay in WB-F344 cells. Each cell suspension of
1 × 104 cells in 200 μL of Dulbecco’s modified Eagle’s medium containing fetal calf serum (3%),
penicillin (100 units/mL), and streptomycin (100 μg/mL) was planted in a 96-well microplate and
precultured for 24 h at 37 °C under a 5% CO2 atmosphere. Fresh medium (200 μL) containing the
positive control bicyclol (purity >99%, Beijing Union Pharmaceutical Factory, Beijing, China) or test
samples were added. After incubation for 1 h, the cells were exposed to 40 mM D-galactosamine for
further 24 h. The cytotoxic effects of test samples were simultaneously measured in the absence of
D-galactosamine. The medium was replaced by 0.5 mg/mL MTT. After 3.5 h incubation, the medium
was removed, and 150 μL of DMSO was added to dissolve the formazan crystals. The optical density
(OD) of the formazan solution was measured at 492 nm using a microplate reader.
3.9.2. Determination of Serum ALT and AST levels
Male ICR mice weighing 18–20 g were purchased from the Beijing Weitonglihua Experimental
Animal Co., Ltd. (Beijing, China). All mice were maintained under controlled conditions and had free
access to standard laboratory chow and water. Animal care and all experimental procedures were
conducted in accordance with the health criteria for care of laboratory animals enacted by the Beijing
municipal government.
The mice were randomly divided into five groups (seven mice/group). The test compounds
suspended in 0.5% CMC-Na were administered orally at a dose of 158 mg/kg (5a), 110 mg/kg (7a)
and 200 mg/kg (bicyclol) at 1, 8 and 24 h before ConA injection, while control mice received an equal
volume of vehicle alone. ConA at a dose of 26 mg/kg was injected intravenously to mice except
normal group. Blood samples were collected at 16 h after ConA treatment. The serum was obtained by
centrifugation at 4000 rpm for 5 min. The levels of ALT and AST were determined using the appropriate
commercial kits (Beijing BHKT Clinical Reagent, Beijing, China).
4. Conclusions
A highly stereoselective synthetic route of goodyeroside A and its analogs starting from (S)-malic
acid has been developed. The absolute configuration of analogs 5 and 7 were confirmed to be the 2R,
3S-configuration via X-ray crystal analysis. Many of the analogs demonstrated hepatoprotective

Molecules 2013, 18
1947
activity in the in vitro GalN-induced hepatocyte injury model while compounds 5a and 7a exhibited
protection comparable to bicyclol. Further in vivo studies demonstrated that the fully acetylated
product 5a significantly decreased the serum levels of ALT and AST in ConA-induced acute liver
injury in mice. Preliminary results from the SAR studies on goodyeroside A and its analogs establish
compound 5a as our new lead for future molecular design and development of a novel hepato-
protective agent.
Supplementary Materials
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/18/2/1933/s1.
Conflicts of Interest
The authors declare no conflicts of interest.
References
1. College, J.N.M. Dictionary of the Traditional Chinese Medicines; Shanghai Scientific
Technologic Publishing House: Shanghai, China, 1986; pp. 2283–2286.
2. Liang, W.L.; Chen, R.C.; Chiang, Y.J.; Su, C.H.; Yang, L.L.; Yen, K.Y. Study on Anoectochilus
Species. Formosan Sci. 1990, 43, 47–58.
3. Gao, W.Y.; Li, Y.M.; Zhu, D.Y. Phenolic Glucosides and a γ-Lactone Glucoside from the Sprouts
of Crocus Sativus. Planta Med. 1999, 65, 425–427.
4. Du, X.M.; Sun, N.Y.; Chen, Y.; Irino, N.; Shoyama, Y. Hepatoprotective Aliphatic Glycosides
from Three Goodyera Species. Biol. Pharm. Bull. 2000, 23, 731–734.
5. Li, X.Y. Bioactivity of Neolignans from Fructus Schizandrae. Mem. Inst. Oswaldo Cruz 1991,
86 (Suppl II), 31–37.
6. Gu, S.J. Bis(Methylenedioxy) Biphenyl Compounds Useful for the Treatment of Liver Diseases.
U.S. Patent 4868207, 19 September 1989.
7. Liu, G.T. Bicyclol: A Novel Drug for Treating Chronic Viral Hepatitis B and C. Med. Chem.
2009, 5, 29–43.
8. Dienstag, J.L.; Schiff, E.R.; Wright, T.L.; Perrillo, R.P.; Hann, H.-W.L.; Goodman, Z.; Crowther, L.;
Condreay, L.D.; Woessner, M.; Rubin, M.; et al. Lamivudine as Initial Treatment for Chronic
Hepatitis B in the United States. N. Engl. J. Med. 1999, 341, 1256–1263.
9. Zhang, F.; Wei, J.; Yin, D.L.; Huang, H.H.; Zhang, Y.H. A Facile Synthesis of Goodyeroside A
from (S)-Malic Acid. Sci. China Ser. B 2009, 52, 2176–2179.
10. Kazumasa, H.; Yoshiro, F.; Shigeo, K.; Yoshikazu, T. Process for Producing 3-Hydroxy-γ-
Butyrolactone Derivatives. US Patent 6268515, 21 July 2001.
11. Schmidt, R.R. New Methods for the Synthesis of Glycosides and Oligosaccharides - Are There
Alternatives to the Koenigs-Knorr Method. Angew. Chem. Int. Ed. Engl. 1986, 25, 212–235.
12. Cook, B.N.; Bhakta, S.; Biegel, T.; Bowman, K.G.; Armstrong, J.I.; Hemmerich, S.; Bertozzi, C.R.
Differential Carbohydrate Recognition of Two Glcnac-6-Sulfotransferases with Possible Roles in
L-Selectin Ligand Biosynthesis. J. Am. Chem. Soc. 2000, 122, 8612–8622.

Molecules 2013, 18
1948
13. Thomas, E.J.; Williams, A.C. A Stereoselective Approach to the δ-Lactone Fragment of the
Lankacidin Antibiotics. J. Chem. Soc. Chem. Comm. 1987, 1987, 992–994.
14. DattaGupta, A.; Singh, R.; Singh, V.K. A Mild and Efficient Method for the Cleavage of
Tert-Butyldimethylsilyl and Tetrahydropyranyl Ethers by Ceric Ammonium Nitrate in Methanol.
Synlett 1996, 1, 69–71.
15. Corey, E.J.; Venkates, A. Protection of Hydroxyl Groups as Tert-Butyldimethylsilyl Derivatives.
J. Am. Chem. Soc. 1972, 94, 6190–6191.
16. Fernandez, A.M.; Plaquevent, J.C.; Duhamel, L. Optically Pure Dihydroxy γ-Alkylated
γ-Butyrolactones Starting from L-Tartaric Acid: Application to Formal and Total Syntheses of
Natural Products. J. Org. Chem. 1997, 62, 4007–4014.
17. Zhang, F.; Zhong, J.L.; Han, B.; Yin, D.L.; Huang, H.H. (2R,3S)-2-Benzyl-3-(2,3,4,6-Tetra-O-
Acetyl-β-D-Glucopyranosyloxy)butanolide. Acta Crystallogr. E 2010, E66, o704.
18. Allen, F.H.; Kennard, O.; Watson, D.G.; Brammer, L.; Orpen, A.G.; Taylor, R. Tables of Bond
Lengths Determined by X-Ray and Neutron-Diffraction. Part 1. Bond Lengths in Organic
Compounds. J. Chem. Soc. Perkin Trans. 2 1987, 1987, S1–S19.
19. Decker, K.; Keppler, D. Galactosamine induced liver injury. Prog. Liver Dis. 1972, 4, 183–199.
20. Tran-Thi, T.A.; Phillips, J.; Falk, H.; Decker, K. Toxicity of D-galactosamine for Rat Hepatocytes
in Monolayer Culture. Exp. Mol. Pathol. 1985, 42, 89–116.
21. Siendones, E.; Fouad, D.; Abou Elella, A.M.; Quintero, A.; Barrera, P.; Muntane, J. Role of Nitric
Oxide in D-galactosamine-induced Cell Death and its Protection by PGE1 in Cultured
Hepatocytes. Nitric Oxide 2003, 8, 133–143.
22. Ishikawa, T.; Kudo, T.; Shigemori, K.; Saito, S. Application of the Silicon-Tether Strategy for
Controlling the Regioselectivity and Diastereoselectivity of Intramolecular Nitrone Cycloadditions
for Aminopolyol Synthesis. J. Am. Chem. Soc. 2000, 122, 7633–7637.
23. Fráter, G. Über die Stereospezifität der alpha-Alkylierung von-Hydroxycarbon säureestern.
Vorläufige Mitteilung. Helv. Chim. Acta 1979, 62, 2825–2828.
24. Zhang, X.; Huang, H.H.; Chen, Q.H. A Novel Total Synthesis of Kinsenoside and Goodyeroside
A Relying on the Efficient Reaction of the Chiral 2(5H)-Furanones. J. Asian Nat. Prod. Res.
2005, 7, 711–721.
Sample Availability: Not available.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).